Source: BMC Cancer. Unidades: FCFRP, FMRP
Subjects: NEOPLASIAS COLORRETAIS, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
UNGARI, Andrea Queiróz et al. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school. BMC Cancer, v. 17, n. 1, 2017Tradução . . Disponível em: https://doi.org/10.1186/s12885-017-3679-5. Acesso em: 18 nov. 2024.APA
Ungari, A. Q., Pereira, L. R. L., Nunes, A. A., & Peria, F. M. (2017). Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school. BMC Cancer, 17( 1). doi:10.1186/s12885-017-3679-5NLM
Ungari AQ, Pereira LRL, Nunes AA, Peria FM. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school [Internet]. BMC Cancer. 2017 ; 17( 1):[citado 2024 nov. 18 ] Available from: https://doi.org/10.1186/s12885-017-3679-5Vancouver
Ungari AQ, Pereira LRL, Nunes AA, Peria FM. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school [Internet]. BMC Cancer. 2017 ; 17( 1):[citado 2024 nov. 18 ] Available from: https://doi.org/10.1186/s12885-017-3679-5
